Apimeds Pharmaceuticals US, Inc. filed a Form 8-K on November 20, 2026, disclosing that on November 12, 2026, it entered into Amendment No. 1 to its Assignment and Transfer Agreement of Certain Apitox Rights with FreeT Inc., clarifying the consideration to be paid for the assigned rights.

Key Highlights

  • Amendment date: The amendment to the Apitox rights agreement was entered into on November 12, 2026, between Apimeds Pharmaceuticals US, Inc. and FreeT Inc.
  • Initial payment: The company is required to issue 350,000 shares of its common stock to FreeT no later than December 1, 2026.
  • Independent valuation: Within sixty days of the amendment date, the company and FreeT shall jointly appoint an independent third-party valuer to determine the fair value of the assigned rights.
  • Additional consideration: If the valuation exceeds the initial payment, the company shall pay the additional amount to FreeT within thirty days of the valuation's completion, in cash, common stock, or a combination, at the company's discretion.
  • Unregistered issuance: The 350,000 shares have not been registered under the Securities Act of 1933, with the company relying on the exemption provided by Section 4(a)(2).
  • Governing law: The assignment agreement and the amendment are governed by the laws of the Republic of Korea, with exclusive jurisdiction in the Seoul Central District Court.

Apimeds Clarifies Apitox Rights Consideration in Amendment with FreeT Inc.

According to the filing, Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) previously entered into an Assignment and Transfer Agreement of Certain Apitox Rights on August 19, 2026, with FreeT Inc., a company organized under the laws of the Republic of Korea. The filing notes that FreeT is the successor to CNP Roen Co., Ltd., which subsequently changed its name to Inscobee Co., Ltd. and is currently known as FreeT Inc. Pursuant to the original agreement, FreeT irrevocably assigned to the company all of its right, title, and interest in certain Apitox-related rights that were originally acquired by CNP Roen Co., Ltd. under an Apitox Rights Transfer Agreement dated June 16, 2015.

The company disclosed that Amendment No. 1, dated November 12, 2026, was entered into "to clarify the consideration paid to FreeT in connection with the Assigned Rights under Article 7 of the Assignment Agreement." Under the terms described in the amendment, the company is to issue 350,000 shares of its common stock to FreeT as the initial payment, no later than December 1, 2026. The filing further states that within sixty days of the amendment date, both parties shall jointly appoint an independent third-party valuer with experience in pharmaceutical and life-sciences rights to determine the fair value of the assigned rights.

The filing also discloses that if the resulting valuation exceeds the value of the initial share payment, the company shall pay the difference to FreeT within thirty days of the valuation's completion. The company retains discretion over whether that additional consideration is paid in cash, common stock, or a combination of both. The 350,000 shares to be issued as the initial payment have not been registered under the Securities Act of 1933, with the company relying on the Section 4(a)(2) exemption from registration, according to the filing.

What Was Disclosed

Apimeds Pharmaceuticals US, Inc. disclosed an amendment to its Apitox rights assignment agreement with FreeT Inc., establishing an initial payment of 350,000 unregistered common shares due by December 1, 2026, and setting out a process for an independent valuation to determine whether additional consideration is owed.